← Russell 3000 cross-section

NVST Envista Holdings Corp

Trailing twelve months to 2026-07-03 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$4.5bn
Revenue TTM
$2.9bn
Net income TTM
$95m
Free cash flow
$248m
Composite score
61.2
Sector rank
#1150

Valuation

P / E
47.2
EV / EBITDA
12.3
EV / sales
1.7
FCF yield
5.53%
Earnings yield vs 10-yr
-2.61pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
3.3%
EBITDA margin
13.6%
ROE
3.1%
ROIC
8.1%
Revenue growth
11.9%

Insider activity, last 90 days

Net open-market
$-0.22m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

For the three and six months ended July 3, 2026, sales derived from customers outside of the United States were 54.5% and 53.7%, respectively, compared to 53.6% and 52.6% for the three and six months ended June 27, 2025, respectively. Foreign Currency Exchange Rates On a period-over-period basis, currency exchange rates positively impacted reported sales by 1.6% and 2.8% for the three and six months ended July 3, 2026 compared to the comparable periods of 2025, primarily due to the weakening U.S. dollar against most major currencies. We exclude sales from acquired businesses in order to provide accurate year over year comparisons. …Envista Holdings Corp, 10-Q, period ended 2026-07-03, filed 2026-08-05

Read the full passage →